We have located links that may give you full text access.
An update on LAMA/LABA combinations for COPD.
Drug and Therapeutics Bulletin 2017 January
The management of symptoms of chronic obstructive pulmonary disease (COPD) typically involves the use of inhaled long-acting bronchodilators. Previously, we have reviewed the long-acting muscarinic antagonists (LAMAs) ▼aclidinium,1 ▼glycopyrronium,2 tiotropium3 and ▼umeclidinium,4 and the long-acting beta2 agonists (LABAs) indacaterol,5 ▼olodaterol,6 and ▼vilanterol (in combination with fluticasone) in the management of COPD.7 Four fixed-dose combinations of a LAMA with a LABA are now available, all indicated as maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. Here, we provide a brief overview of the four combinations and consider the place of a LAMA/LABA in people with COPD and any factors that might help to choose between them.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app